Pharmafile Logo
Pharmafocus logo
Advanced Search

Bayer

Showing 15 posts of 258 posts found.

NICE gives final draft guidance on two key cancer drugs

October 12, 2017
Sales and Marketing Bayer, CDF, Cancer, Cancer Drugs Fund, Erivedge, NICE, Roche, Stivarga

NICE has announced it has published its final draft guidance for two cancer treatments, covering Bayer’s Stivarga (regorafenib) in the …

News
bayer_cross_2

Bayer forced to halt huge study into key drug

October 6, 2017
Medical Communications, Research and Development Bayer, Janssen, Xarelto, biotech, drugs, pharma, pharmaceutical

Bayer, and development partner Janssen, have been forced to stop a Phase 3 trial looking at expanding the indication of …

News

NICE recommends Bayer’s Eylea for myopic chorodial neovascularisation

September 22, 2017
Medical Communications, Sales and Marketing Bayer, Eylea, NICE, pharma, pharmaceutical

Bayer has revealed that UK drug regulator NICE has given its final recommendation on blockbuster eye drug Eylea (aflibercept solution …

News
Bayer image

Bayer pulls plug on sterilisation device after numerous complaints

September 21, 2017
Sales and Marketing Bayer, Essure, biotech, drugs, pharma, pharmaceutical

Bayer has stopped the commercial sale of a sterilisation device in all countries, except the US, after reports that it …

News

Bayer lymphoma treatment speeds to FDA approval

September 18, 2017
Sales and Marketing Aliqopa, Bayer, biotech, drugs, pharma, pharmaceutical

The FDA gave Bayer priority review for its treatment Aliqopa (copanlisib) in May of this year, and it quickly came …

News
casebia_logo1_rgb

Casebia Therapeutics bolsters leadership by bringing in two new faces

September 8, 2017
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bayer, CRISPR Therapeutics, Casebia Therapeutics, biotech, drugs, pharma, pharmaceutical

Casebia therapeutics, a joint venture between Bayer and CRISPR Therapeutics, has moved to strengthen its leadership team by bringing in …

Appointment

Bayer’s liver cancer drug availability spreads to UK with NICE approval

August 10, 2017
Sales and Marketing Bayer, Cancer, NICE, Nexavar, life sciences, liver cancer, pharma, pharmaceutical

NICE has announced that it has given final appraisal recommending Bayer’s Nexavar (sorafenib) for the treatment of advanced hepatocellular carcinoma …

News

Bayer secures one-two treatment for liver cancer after EU approval

August 7, 2017
Sales and Marketing Bayer, biotech, drugs, pharma, pharmaceutical

Bayer has announced that it has received European Commission approval for its treatment of hepatocellular carcinoma, a type of liver …

News

Bayer celebrates FDA priority review for investigational blood cancer drug

May 17, 2017
Research and Development, Sales and Marketing Bayer, FDA, blood cancer

Bayer has announced that its investigational blood cancer treatment copanlisib has been awarded priority review designation from the FDA, meaning …

News
bayer_cross_2

FDA approves first new drug for liver cancer in decade

April 28, 2017
Medical Communications, Sales and Marketing Bayer, Stivarga, hepatocellular carcinoma, liver cancer

The FDA has announced that it has approved the first new treatment for hepatocellular carcinoma (HCC), a type of liver …

News
pregnant-1245703_960_720

Pregnancy test pill used through 60s & 70s connected with birth defects

March 20, 2017
Medical Communications, Sales and Marketing Bayer, Primodos

A pregnancy test, named Primodos, which was taken by 1.5 million British mothers and was linked to birth defects, may …

News

Bayer’s cardiovascular drug races to target in trial

February 9, 2017
Research and Development, Sales and Marketing Bayer, Janssen, Xarelto

Bayer has been putting its blood-thinning drug, Xarelto, through its paces in a Phase 3 trial to determine whether it …

News
money-256281_960_720

Five most talked about mergers and acquisitions of 2016

January 27, 2017
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Actavis, Bayer, Boehringer, Johnson & Johnson, Sanofi, Teva, acquisition, mergers, monsanto, pharma

2017 has kicked off with a bang – as Johnson & Johnson confirmed a $30 billion deal to takeover of …

Feature

Looking back at the biggest deal of 2016: Bayer-Monsanto

December 2, 2016
Medical Communications Bayer, acquisition, big deal, monsanto, pharma deal 2016

The industry followed Bayer’s attempts to acquire US agricultural firm Monsanto with fevered anticipation; the takeover eventually closed in September …

News
germany-flag-flying-german-breeze-flag-pole-waving-1398668

Roche, Bayer and more speak out against German pricing cap plans

November 14, 2016
Sales and Marketing Bayer, Germany, Roche

A number of major drug manufacturers have spoken out against German government plans to cap prescription drug pricing in the …

News

Latest content

GSK shares data from global shingles survey

December 1, 2023

AbbVie to acquire ImmunoGen for approximately $10.1bn

December 1, 2023

FDA accepts NDA for Karuna’s schizophrenia treatment

November 30, 2023

Vivos Therapeutics gains FDA 510(k) clearance for sleep apnea treatment device

November 30, 2023

Tolremo doses first patient in phase 1 trial for drug to combat transcriptional cancer drug resistance

November 29, 2023